AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Article Link
Collect
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Case Report | Open Access

A rare case of pulmonary adenoid cystic carcinoma with liver metastases treated effectively with stereotactic body radiation therapy

Swe Swe Hlaing1( )Rachelle Lanciano2Emeka Ugwuebulem3Soe Htet Arker4Kumar Sarvottam5Stephen Shore1Jing Feng2
Crozer Health, Springfield, Pennsylvania, USA
Crozer Health/Philadelphia CyberKnife, Springfield, Pennsylvania, USA
St. Luke's University Health, Bethlehem, Pennsylvania, USA
Albany Medical Center, Albany, New York, USA
Einstein Medical Center, Philadelphia, Pennsylvania, USA
Show Author Information

Abstract

Pulmonary adenoid cystic carcinoma (PACC) is an extremely rare neoplasm. Adenoid cystic carcinoma (ACC) usually occurs in the salivary glands of the head and neck. Given its rare occurrence, there are no established guidelines for the treatment of progressive and/or relapsed disease. We herein report a case of a 57-year-old female who was incidentally found to have biopsy confirmed PACC following trauma diagnostic workup. She underwent pneumonectomy and adjuvant radiation therapy with an initial good response. On follow-up a year later, she was noted to have two metastatic liver lesions treated with stereotactic body radiation therapy (SBRT) and lenvatinib. This case report adds to the growing area of research on PACC, especially among patients requiring SBRT for oligometastatic disease.

References

1

Hu MM, Hu Y, He JB, Li BL. Primary adenoid cystic carcinoma of the lung: clinicopathological features, treatment and results. Oncol Lett. 2015;9(3):1475-1481. https://doi.org/10.3892/ol.2015.2859

2

Reid JD. Adenoid cystic carcinoma (cylindroma) of the bronchial tree. Cancer. 1952;5(4):685-694.

4

Krifa M, Bdioui A, Lajmi Z, Missaoui N, Hmissa S, Mokni M. Primary adenoid cystic carcinoma of the lung: a case report and literature review. Heliyon. 2021;7(2):e06206.

5

Takanori K, Tomofumi Y, Tadashi U, Chie U, Hiroshi A, Ichiro Y. Ichinode Yokito: treatment outcome of resected and nonresected primary adenoid cystic carcinoma of the lung. Ann Thorac Cardiovasc Surg. 2002;8:74-77.

6

Jaso J, Malhotra R. Adenoid cystic carcinoma. Arch Pathol Lab Med. 2011;135(4):511-515.

7

Moran CA, Koss MN, Suster S. Primary adenoid cystic carcinoma of the lung. A clinicopathologic and immunohistochemical study of 16 cases. Cancer. 1994;73(5):1390-1397.

8

Mondal A, Saha DK. Primary adenoid cystic carcinoma of the lung: a clinicopathologic study. Indian J Thorac Cardiovasc Surg. 2008;24(4):240-243.

9

Persson M, Andrén Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci. 2009;106(44):18740-18744.

10

Persson M, Andrén Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci. 2009;106(44):18740-18744.

11

Frierson HF, Moskaluk CA. Moskaluk - Mutation signature of adenoid cystic carcinoma: evidence for transcriptional and epigenetic reprogramming. J Clin Invest. 2013;123(7):2783-2785. https://doi.org/10.1172/JCI69070

12

Mitani Y, Li J, Rao PH, et al. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significanceMYB-NFIB fusion in salivary adenoid cystic carcinoma. Clin Cancer Res. 2010;16(19):4722-4731.

13

Wang Y, Cai S, Gao S, et al. Tracheobronchial adenoid cystic carcinoma:50-year experience at the National Cancer Center, China. Ann Thorac Surg, 2019;108(3), 873-882. https://doi.org/10.1016/j.athoracsur.2019.03.065

14

Tyan K, Bae JE, Lorch JH, et al. Oligometastatic adenoid cystic carcinoma: correlating tumor burden and time to treatment with outcomes. Head Neck. 2022;44(3):722-734. https://doi.org/10.1002/hed.26964

15

Franzese C, Badalamenti M, Teriaca A, et al. Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer. J Cancer Res Clin Oncol. 2021;147(5):1307-1313. https://doi.org/10.1007/s00432-021-03518-5

16

Mahadevan A, Blanck O, Lanciano R, et al. Stereotactic Body Radiotherapy (SBRT) for liver metastasis – clinical outcomes from the international multi-institutional RSSearch® Patient Registry. Radiat Oncol. 2018;13:26. https://doi.org/10.1186/s13014-018-0969-2

17
Sahara S, Herzog AE, Nör JE. Systemic therapies for salivary gland adenoid cystic carcinoma. Am J Cancer Res. 2021;11(9):4092-4110. Published 2021 Sep 15.
18

Laurie SA, Ho AL, Fury MG, Sherman E, Pfister DG. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol. 2011;12(8):815-824.

19
Keam B, Kim SB, Shin SH, et al. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer. 2015;121(15):2612-2617. Epub 2015 Apr 22. https://doi.org/10.1002/cncr.29401
20

Tchekmedyian V, Sherman EJ, Dunn L, et al. Phase Ⅱ study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol. 2019;37(18):1529.

21
Wong SJ, Karrison T, Hayes DN, et al. Phase Ⅱ trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016;27(2):318-323. Epub 2015 Nov 23. 10.1093/annonc/mdv537
22

Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1):e173501. https://doi.org/10.1001/jamaoncol.2017.3501

23

Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet (London, England). 2019;393(10185):2051-2058. https://doi.org/10.1016/S0140-6736(18)32487-5

Precision Radiation Oncology
Pages 335-340
Cite this article:
Hlaing SS, Lanciano R, Ugwuebulem E, et al. A rare case of pulmonary adenoid cystic carcinoma with liver metastases treated effectively with stereotactic body radiation therapy. Precision Radiation Oncology, 2022, 6(4): 335-340. https://doi.org/10.1002/pro6.1178

447

Views

0

Crossref

0

Scopus

Altmetrics

Received: 30 August 2022
Revised: 30 October 2022
Accepted: 31 October 2022
Published: 26 November 2022
© 2022 The Authors. Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Return